Tenders for biosimilars for Humira in both Denmark and Italy mark a dramatic shift https://t.co/ksFIxmvmJC insights… https://t.co/Ey3zHoDwZD
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Our pricing and reimbursement research presented at ISPOR Europe
14 November 2018
Milena Izmirlieva
In research, presented at the ISPOR Europe meeting in Barcelona on 13 October, Associate Director Milena Izmirlieva examines the impact of securing marketing approval under an expedited pathway on pricing and reimbursement outcomes.
Related Posts
-
-
-
-
-
-
-
-
Explore
RELATED INDUSTRIES & TOPICS
Follow Us
The impact of expedited marketing authorization on P&R outcomes for drugs in the US and EU-5 #ISPORbarcelona check… https://t.co/mGbWzVhygs
International reference pricing of pharmaceuticals: Apply liberally or use sparingly? See our research from… https://t.co/d7R2S7KZVJ
We are at ISPOR Europe 2018 in Barcelona, Spain! Come see our posters tomorrow at 8:30 PHP359 and PHP48